Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Non-Current Deffered Revenue: 2020-2024

Historic Non-Current Deffered Revenue for Cidara Therapeutics (CDTX) over the last 3 years, with Mar 2024 value amounting to $1.9 million.

  • Cidara Therapeutics' Non-Current Deffered Revenue fell 90.26% to $1.9 million in Q1 2024 from the same period last year, while for Mar 2024 it was $1.9 million, marking a year-over-year decrease of 90.26%. This contributed to the annual value of $4.2 million for FY2023, which is 79.32% down from last year.
  • Cidara Therapeutics' Non-Current Deffered Revenue amounted to $1.9 million in Q1 2024, which was down 55.52% from $4.2 million recorded in Q4 2023.
  • In the past 5 years, Cidara Therapeutics' Non-Current Deffered Revenue ranged from a high of $24.4 million in Q3 2022 and a low of $1.9 million during Q1 2024.
  • Over the past 3 years, Cidara Therapeutics' median Non-Current Deffered Revenue value was $17.2 million (recorded in 2022), while the average stood at $15.2 million.
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first soared by 65.21% in 2021, then plummeted by 90.26% in 2024.
  • Cidara Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $11.1 million in 2020, then spiked by 65.21% to $18.4 million in 2021, then increased by 11.47% to $20.5 million in 2022, then crashed by 79.32% to $4.2 million in 2023, then slumped by 90.26% to $1.9 million in 2024.
  • Its Non-Current Deffered Revenue stands at $1.9 million for Q1 2024, versus $4.2 million for Q4 2023 and $16.5 million for Q3 2023.